Human ALCAM / CD166 Protein (His Tag)

CD166,MEMD

100ug (NPP3673) Please inquiry

Catalog Number	P10045-H08H
Organism Species	Human
Host	Human Cells
Synonyms	CD166,MEMD
Molecular Weight	The recombinant human ALCAM consists of 510 amino acids and has a calculated molecular mass of 57.4 kDa. As a result of glycosylation, rh ALCAM migrates as an approximately 60-70 kDa band in SDS-PAGE under reducing conditions.
predicted N	Trp 28
SDS-PAGE
Purity	> 98 % as determined by SDS-PAGE
Protein Construction	A DNA sequence encoding the extracellular domain (Met 1-Ala 526) of human ALCAM (NP_001618.2) was expressed, with the C-terminal polyhistidine tag.
Bio-activity	Immobilized human ALCAM-His at 10 μg/ml (100 μl/well) can bind mouse CD6-Fc (P50711-M02H), The EC₅₀ of mouse CD6-Fc (P50711-M02H) is 0.1-0.22 μg/ml.
Research Area	Developmental Biology \|Embryogenesis \|Germ Layer Formation \|Mesoderm Marker
Formulation	Lyophilized from sterile PBS, pH 7.4 1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
Background	Activated leukocyte cell adhesion molecule (ALCAM)/Cluster of differentiation (CD166) is a type I transmembrane cell adhesion molecule belonging to the Ig superfamily and a ligand for CD6 that is expressed on T lymphocytes. The extracellular domain of ALCAM contains five Ig-like domains (three Ig-like C2-type domains and two Ig-like V-type domains), of which the amino-terminal V1 domain is essential for ligand binding and ALCAM-mediated cell aggregation. ALCAM mediates both heterophilic (ALCAM-CD6) and homophilic (ALCAM-ALCAM) cell-cell interactions. ALCAM/CD6 interaction plays a role in T cell development and T cell regulation, as well as in the binding of T- and B-cells to activated leukocytes. Recently, homophilic (ALCAM-ALCAM) adhesion was shown to play important roles in tight cell-to-cell interaction and regulation of stem cell differentiation. While expressed in a wide variety of tissues, ALCAM is usually restricted to subsets of cells involved in dynamic growth and/or migration, including neural development, branching organ development, hematopoiesis, immune response and tumor progression. And CD166 is regarded as a potential novel breast cancer indicator and therapeutic target.
Reference	Swart GW. (2002) Activated leukocyte cell adhesion molecule (CD166/ALCAM): developmental and mechanistic aspects of cell clustering and cell migration. Eur J Cell Biol. 81(6): 313-21. Fujiwara H, et al. (2003) Human blastocysts and endometrial epithelial cells express activated leukocyte cell adhesion molecule (ALCAM/CD166). J Clin Endocrinol Metab. 88(7): 3437-43. Jezierska A, et al. (2006) ALCAM/CD166 protects breast cancer cells against apoptosis and autophagy. Med Sci Monit. 12(8): BR263-73. Kahlert C, et al. (2009) Increased expression of ALCAM/CD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapse. Br J Cancer. 101(3): 457-64.